Halozyme Therapeutics (NASDAQ:HALO) Earns "Buy" Rating from HC Wainwright

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report)'s stock had its "buy" rating restated by HC Wainwright in a report issued on Wednesday, Benzinga reports. They presently have a $50.00 price target on the biopharmaceutical company's stock. HC Wainwright's price objective indicates a potential upside of 31.51% from the stock's current price.

Several other research firms also recently weighed in on HALO. TheStreet downgraded Halozyme Therapeutics from a "b-" rating to a "c+" rating in a research report on Monday, January 22nd. The Goldman Sachs Group reduced their target price on Halozyme Therapeutics from $45.00 to $40.00 and set a "neutral" rating on the stock in a research report on Thursday, January 18th. StockNews.com upgraded Halozyme Therapeutics from a "hold" rating to a "buy" rating in a research report on Friday, February 23rd. Morgan Stanley reduced their target price on Halozyme Therapeutics from $61.00 to $59.00 and set an "overweight" rating on the stock in a research report on Tuesday, December 26th. Finally, Benchmark reiterated a "buy" rating and set a $50.00 target price on shares of Halozyme Therapeutics in a research report on Tuesday. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $53.29.

Halozyme Therapeutics Price Performance

Shares of NASDAQ:HALO traded down $0.36 on Wednesday, hitting $38.02. The company had a trading volume of 733,857 shares, compared to its average volume of 1,278,183. The company has a current ratio of 6.64, a quick ratio of 5.50 and a debt-to-equity ratio of 17.89. Halozyme Therapeutics has a 52-week low of $29.85 and a 52-week high of $45.00. The business has a 50 day moving average of $39.44 and a 200 day moving average of $37.76. The company has a market cap of $4.83 billion, a PE ratio of 18.02, a PEG ratio of 0.47 and a beta of 1.25.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last issued its quarterly earnings data on Tuesday, February 20th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.77 by ($0.02). Halozyme Therapeutics had a net margin of 33.96% and a return on equity of 248.20%. The company had revenue of $230.04 million during the quarter, compared to analysts' expectations of $235.25 million. As a group, equities analysts anticipate that Halozyme Therapeutics will post 3.33 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Halozyme Therapeutics news, SVP Michael J. Labarre sold 10,000 shares of the company's stock in a transaction dated Tuesday, March 12th. The stock was sold at an average price of $41.64, for a total transaction of $416,400.00. Following the completion of the sale, the senior vice president now directly owns 156,558 shares in the company, valued at $6,519,075.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders sold 30,000 shares of company stock worth $1,196,800 over the last three months. 2.70% of the stock is owned by insiders.

Institutional Investors Weigh In On Halozyme Therapeutics

A number of large investors have recently modified their holdings of HALO. US Bancorp DE grew its stake in shares of Halozyme Therapeutics by 43.8% in the first quarter. US Bancorp DE now owns 12,663 shares of the biopharmaceutical company's stock valued at $506,000 after buying an additional 3,859 shares in the last quarter. HighTower Advisors LLC grew its stake in Halozyme Therapeutics by 7.3% during the 1st quarter. HighTower Advisors LLC now owns 11,952 shares of the biopharmaceutical company's stock valued at $477,000 after purchasing an additional 812 shares in the last quarter. PNC Financial Services Group Inc. grew its stake in Halozyme Therapeutics by 31.9% during the 1st quarter. PNC Financial Services Group Inc. now owns 16,826 shares of the biopharmaceutical company's stock valued at $671,000 after purchasing an additional 4,066 shares in the last quarter. Natixis Advisors L.P. grew its stake in Halozyme Therapeutics by 14.9% during the 1st quarter. Natixis Advisors L.P. now owns 30,219 shares of the biopharmaceutical company's stock valued at $1,205,000 after purchasing an additional 3,928 shares in the last quarter. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS grew its stake in Halozyme Therapeutics by 10.5% during the 1st quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 51,597 shares of the biopharmaceutical company's stock valued at $2,058,000 after purchasing an additional 4,920 shares in the last quarter. Institutional investors and hedge funds own 97.79% of the company's stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.